|Articles|February 1, 2011
- BioPharm International-02-01-2011
- Volume 24
- Issue 2
BioPharm International, February 2011 Issue (PDF)
The Quality Product Steward Model
Advertisement
Articles in this issue
over 14 years ago
The Quality Product Steward Model: The Genentech Approachover 14 years ago
An Economic Comparison of Three Cell Culture Techniquesover 14 years ago
The Powerful Lesson of the GSK–Whistleblower Caseover 14 years ago
Trends Toward Standardizationover 14 years ago
Congress to Scrutinize FDA Rules, Research Policiesover 14 years ago
What a Piece of Work is PharmaNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
